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ABSTRACT
Type 1 diabetes is a disease characterized by destruction of pancreatic b-cells, which leads
to absolute deficiency of insulin secretion. Depending on the manner of onset and pro-
gression, it is classified as fulminant, acute-onset or slowly progressive type 1 diabetes.
Here, we propose the diagnostic criteria for acute-onset type 1 diabetes mellitus. Among
the patients who develop ketosis or diabetic ketoacidosis within 3 months after the onset
of hyperglycemic symptoms and require insulin treatment continuously after the diagnosis
of diabetes, those with anti-islet autoantibodies are diagnosed with ‘acute-onset type 1
diabetes mellitus (autoimmune)’. In contrast, those whose endogenous insulin secretion is
exhausted (fasting serum C-peptide immunoreactivity <0.6 ng/mL) without verifiable anti-
islet autoantibodies are diagnosed simply with ‘acute-onset type 1 diabetes mellitus’.
Patients should be reevaluated after certain periods in case their statuses of anti-islet au-
toantibodies and/or endogenous insulin secretory capacity are unknown.
INTRODUCTION
Type 1 diabetes is a disease characterized by the destruction of
pancreatic b-cells, which leads to absolute deficiency of insulin
secretion. Depending on the manner of onset and progression,
it is classified as fulminant, acute-onset or slowly progressive
type 1 diabetes in Japan1. The diagnostic criteria for type 1 dia-
betes have not been established in Western countries, because
the clinical characteristics of Caucasian patients with type 1 dia-
betes are relatively homogenous, and it is conjectured that type
1 diabetes has been recognized to be easily distinguished from
other types of diabetes by their age of onset, the presence or
absence of obesity, and mode of disease onset. However, with
rising obesity rates in children, it has been reported that it is
increasingly difficult to differentiate between type 1 diabetes
and type 2 diabetes2. Therefore, it is speculated that, in the near
future, investigation towards a decision on the diagnostic crite-
ria or guidelines to discriminate between both types of diabetes
will be made in Western countries.
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SPECIAL REPORT
Although most cases of type 2 diabetes remain in a non-
insulin-dependent state, it is known that some patients progress
to an insulin-dependent state as a result of exhausting their
endogenous insulin secretion. The term ‘insulin-dependent
state’ means that insulin treatment is essential to sustain life,
whereas patients whose conditions do not require insulin treat-
ment for survival, but require insulin injections for glycemic
control, are considered to be in a non-insulin-dependent state1.
Therefore, the diagnostic criteria that can distinguish type 1
diabetes from type 2 diabetes with insulin-dependent state are
important for general practitioners. Here, we propose the diag-
nostic criteria for acute-onset type 1 diabetes mellitus.
DIAGNOSTIC CRITERIA FOR ACUTE-ONSET TYPE 1
DIABETES MELLITUS (2012)
Table 1 shows the diagnostic criteria for acute-onset type 1 dia-
betes mellitus (2012). As previously reported diagnostic criteria
for fulminant type 1 diabetes3, it was taken as the 2012 version
because of the possibility of revision. In order to establish the
diagnostic criteria for ‘typical acute-onset type 1 diabetes’,
which can be used easily by general practitioners and can be
adapted to long-standing patients, we selected the following
three conditions as criteria: (i) acute-onset type; (ii) the need
for continuous insulin therapy; and (iii) anti-islet autoantibody
status. Patients are diagnosed as having ‘acute-onset type 1 dia-
betes mellitus (autoimmune)’ if they are positive for anti-islet
autoantibodies, whereas they are diagnosed simply as having
‘acute-onset type 1 diabetes mellitus’ if their endogenous insulin
secretion is exhausted without verifiable anti-islet autoantibod-
ies. However, reassessment is required after certain periods in
case the statuses of anti-islet autoantibodies and/or endogenous
insulin secretory capacity are unknown. Although patients are
diagnosed as having ‘acute-onset type 1 diabetes mellitus (idio-
pathic)’ if they are negative for autoantibodies to glutamic acid
decarboxylase (GADA), insulinoma-associated antigen 2 (IA-
2A), insulin (IAA) and zinc transporter-8 (ZnT8A) at the onset
of diabetes, this category was not included in the present diag-
nostic criteria, because it is difficult to measure all of these au-
toantibodies at the clinic. Based on the previous reports, the
prevalence of acute-onset type 1 diabetes (idiopathic) is esti-
mated to be <10% of patients with acute-onset type 1 diabetes
in Japan4–6.
As described in the ‘Notes’ in these criteria, a state of ketosis
should be confirmed by the elevation of urine and/or serum ke-
tone bodies. It is noted that diabetic ketosis or ketoacidosis
might not be seen in patients in whom insulin therapy was
started immediately after the occurrence of hyperglycemia and/
or hyperglycemic symptoms. Furthermore, we added a com-
ment on the ‘honeymoon period’, which is observed in approx-
imately 30% of patients with acute-onset type 1 diabetes7. We
also described a comment that ‘IAA should be evaluated before
or shortly after insulin therapy is initiated’, because IAA and
insulin antibodies developed by exposure to exogenous insulin
are currently indistinguishable.
CUT-OFF LEVEL FOR ENDOGENOUS INSULIN
DEFICIENCY
In the present diagnostic criteria, we defined ‘endogenous insu-
lin deficiency’ as fasting serum C-peptide immunoreactivity
(CPR) <0.6 ng/mL. The bases on this definition are as follows.
As we have not found any clear evidence demonstrating the
definition of endogenous insulin deficiency in Japan, we created
a cut-off value based on CPR data collected from our hospitals
and literature previously reported from outside of Japan.
First, 123 patients (56 males, 65 females and two unknown)
whose duration of hyperglycemic symptoms before the initia-
tion of insulin therapy was <3 months and who did not meet
the diagnostic criteria for fulminant type 1 diabetes were
selected from our previous study8. Of these 123 patients, fasting
serum CPR values were available in 48 patients and were used
to determination the cut-off value. As shown in Figure 1, the
fasting serum CPR value was distributed from <0.1 to 1.4 ng/
mL, and the mean level was 0.61 – 0.42 ng/mL (mean – stan-
dard deviation). Furthermore, the median level and 10th, 25th,
50th, 75th and 90th percentiles were 0.55 ng/mL, and 0.10,
Table 1 | Diagnostic criteria for acute-onset type 1 diabetes mellitus
(2012)
1. Occurrence of diabetic ketosis or ketoacidosis around <3 months
after the onset of hyperglycemic symptoms (thirst, polydipsia,
polyuria, weight loss)†
2. Need for continuous insulin therapy after the diagnosis of diabetes
mellitus‡
3. Positive test result for anti-islet autoantibodies§
4. Presence of endogenous insulin deficiency without verifiable anti-islet
autoantibodies¶
‘Acute-onset type 1 diabetes mellitus (autoimmune)’: fulfilled
criteria 1, 2 and 3.
‘Acute-onset type 1 diabetes mellitus’: fulfilled criteria 1, 2 and 4.
Re-evaluation is required after a certain period in case the status of
anti-islet autoantibodies and/or endogenous insulin secretory capacity
is unknown.
†The presence of ketosis should be confirmed by the elevation of urine
and/or serum ketone bodies. Diabetic ketosis or ketoacidosis might not
be seen in patients in whom insulin therapy was started immediately
after the occurrence of hyperglycemia and/or hyperglycemic symp-
toms. ‡‘Continuous insulin therapy’ includes restart of insulin therapy
after a transient period of being able to withdraw insulin therapy after
initiation of treatment (honeymoon period). §‘Positive test result for
anti-islet autoantibodies’ is defined as when one or more of the follow-
ing autoantibodies are positive at any time during the course of the
disease; islet cell autoantibodies, glutamic acid decarboxylase autoanti-
bodies, insulinoma-associated antigen 2 autoantibodies or insulin au-
toantibodies. However, insulin autoantibodies should be evaluated
before or shortly after insulin therapy is initiated. ¶‘Endogenous insulin
deficiency’ is defined as fasting serum C-peptide immunoreactivity
<0.6 ng/mL. Patients should be diagnosed as having fulminant type 1
diabetes when its diagnostic criteria are fulfilled. Monogenic diseases
need to be discriminated.
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0.24, 0.55, 0.90 and 1.17 ng/mL, respectively. In Caucasian
patients with diabetes, Gjessing et al.9 reported that fasting
serum CPR <0.2 nmol/L (0.6 ng/mL) gives a good distinction
between ketosis-onset type 1 and type 2 diabetes, and the posi-
tive and negative predictive values were 83% (95% confidence
interval [CI] 70–93%) and 86% (95% CI 76–92%) in patients
including recent-onset diabetes. and 97% (95% CI 86–100%)
and 86% (95% CI 76–93%) in patients with a duration of dia-
betes >2 years. Furthermore, in Taiwanese patients with child-
hood-onset type 1 diabetes, Tung et al.10 reported that median
fasting serum CPR level was 0.2 nmol/L (0.6 ng/mL) at disease
onset. Based on these data, we decided to use ‘fasting serum
CPR <0.6 ng/mL’ as a definition of endogenous insulin defi-
ciency. The assay procedure for determination of CPR levels
has been improved, and sensitive CPR immunoassays, which
do not cross-react with proinsulin, have recently come into
wide use instead of the conventional radioimmunoassay
method. The evaluation of the cut-off value for endogenous
insulin deficiency might be required using newly developed
assays in the future.
DISCUSSION
Japanese patients with type 1 diabetes are classified into fulmin-
ant, acute-onset or slowly progressive type 1 diabetes depending
on the manner of onset and progression. Diagnostic criteria for
fulminant type 1 diabetes, which were established in 2004 and
revised in 2012, are widely used in general medicine8. We are
also in the process of establishing diagnostic criteria for slowly
progressive type 1 diabetes. One of the reasons we decided to
establish diagnostic criteria for acute-onset type 1 diabetes is
that there are no tools that general practitioners can use to
appropriately and easily diagnose type 1 diabetes. As the treat-
ment of type 1 diabetes has changed in recent years, such as
the introduction of dietary therapy using carbohydrate counting
and the development of new insulin analogs, it would be desir-
able for suitable treatment to be based on the correct diagnosis
of type 1 diabetes. Furthermore, as it is also important to start
insulin treatment immediately when type 1 diabetes is sus-
pected, diagnostic criteria that can be used easily are urgently
required. In contrast, establishment of diagnostic criteria for
‘typical’ cases enables discussions using the same criteria in the
research fields, which is important for the investigation of the
pathogenesis of type 1 diabetes.
In establishing these diagnostic criteria, we discussed which
is more suitable, between <3 months and <6 months as the
period from the onset of hyperglycemic symptoms to initiation
of insulin therapy, and concluded to use the former from a
view point of the criteria of typical cases with acute-onset type
1 diabetes. Furthermore, we made a criterion, ‘Need for contin-
uous insulin therapy after the diagnosis of diabetes mellitus’,
because insulin-treated diabetic patients do not necessarily have
type 1 diabetes, and patients with ‘soft-drink ketosis’ have
acute-onset diabetes, but can withdraw insulin therapy after
several months. As anti-islet autoantibodies, which are the hall-
mark of autoimmunity, can disappear after years of diabetes
being present, it is important to prove endogenous insulin defi-
ciency in patients with long-standing diabetes if they have no
anti-islet autoantibodies. ‘Acute-onset type 1 diabetes mellitus’
can be diagnosed when endogenous insulin deficiency is
proved, even if anti-islet autoantibodies are negative, but reas-
sessment is required after a certain period in patients with pre-
served endogenous insulin secretion. Patients should not be
diagnosed as having ‘acute-onset type 1 diabetes mellitus (idio-
pathic)’ even if their GADA, IA-2A, IAA and ZnT8A are all
negative during the follow up, except for the case where those
autoantibodies were measured at the onset of diabetes. This is
because we cannot exclude the possibility that anti-islet autoan-
tibodies were positive soon after the development of type 1 dia-
betes. Tanaka et al.11 recently reported for the Committee on
Type 1 Diabetes, Japan Diabetes Society that the prevalence of
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Figure 1 | Distribution of fasting serum C-peptide immunoreactivity
(CPR) levels in patients with acute-onset type 1 diabetes. (a) Histogram.
(b) Box plot.
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duration of <5 years was 12.5% (8/64) and 13.8% (8/58) when
six patients with fulminant type 1 diabetes were excluded.
However, it should be noted that there is a possibility that
autoantibody-negative patients might include patients whose
anti-islet autoantibodies were positive at disease onset, but
became negative within 5 years.
It is well known that genetic factors including human leuko-
cyte antigen genes are associated with the development of type
1 diabetes. Kawabata et al.12 reported as a report of the Com-
mittee on Type 1 Diabetes, Japan Diabetes Society
that DRB1*04:05-DQB1*04:01, DRB1*08:02-DQB1*03:02 and
DRB1*09:01-DQB1*03:03 were positively associated, and
DRB1*15:01-DQB1*06:02 and DRB1*15:02-DQB1*06:01 were
negatively associated with Japanese patients with acute-onset
type 1 diabetes. We did not include the criteria on human leu-
kocyte antigen, because the presence of susceptible haplotypes
in patients with suspected acute-onset type 1 diabetes does not
lead to a definite diagnosis, and the presence of protective hapl-
otypes cannot exclude type 1 diabetes completely.
Although serum and urinary CPR have been conventionally
used for the assessment of endogenous insulin secretory capac-
ity, we have omitted urinary CPR from these diagnostic criteria
as measurement of serum CPR is currently an international
standard13. Furthermore, we used fasting serum CPR because
tolerance tests, such as intravenous glucagon stimulatory test or
mixed meal test, are difficult to manipulate in general practice.
CONCLUSION
We proposed diagnostic criteria for acute-onset type 1 diabetes
mellitus (2012). We hope that acute-onset type 1 diabetes will
be diagnosed precisely using these new criteria both in clinical
medicine and research fields.
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